从儿科德尔戈西提尼布阿托皮性皮肤炎试验的后期安全性/有效性分析
Tatsuki Fukuie1, Hiroyuki Toyama2, Mai Tanaka2
1Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
概括
德尔戈西替尼0.5%膏在轻度儿科亚托皮性皮肤炎中可能比0.25%剂量更有效. 德尔戈西提尼布膏在与其他治疗相结合时,对儿童来说是安全的,并且耐受性良好.
科学领域:
- 皮肤病学 皮肤病学
- 儿科无形皮肤炎的皮肤炎.
- 药理学 药理学是指药理学的学科.
背景情况:
- 德尔戈西提尼布膏用于儿科亚托邦性皮肤炎,通常为0.25%,严重病例可选择0.5%.
- 目前的治疗指南缺乏德尔戈西提尼布的具体剂量标准.
- 与其他局部治疗联合使用delgocitinib的安全性尚未得到充分证实.
研究的目的:
- 为了比较0.25%和0.5%的delgocitinib药膏配方在儿科阿托皮性皮肤炎中的疗效和安全性.
- 调查delgocitinib与局部皮质类固醇和/或塔克罗利木斯膏同时使用时的安全性.
主要方法:
- 对两项临床试验的数据进行后期分析,其中涉及患有亚托皮性皮肤炎的儿科患者.
- 在治疗4周和56周后对疗效和安全性的评估.
- 基于基线疾病严重程度的剂量反应关系的评估.
主要成果:
- 对于轻度的亚托邦性皮炎,71.4%的患者获得了0.5%的delgocitinib清晰或几乎清晰的皮肤,而46.2%的患者获得了0.25%.
- 对于中度至严重的亚托皮性皮炎,有效率在0.25% (19.0%) 和0.5% (20.0%) 剂量之间是相似的.
- 在两种剂量之间或与同时治疗有关的安全性概况中没有发现显著差异.
结论:
- 德尔戈西提尼布0.5%膏在治疗4周后,可能为轻度儿科亚托皮炎提供更高的疗效.
- 德尔戈西提尼布膏在儿童患者中表现出良好的耐受性,当与局部皮质类固醇和/或塔克罗利斯膏结合使用时长达56周.
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...